BACKGROUND: Prognosis of patients with relapsed Ewing sarcoma (ES) is poor. The 5-year overall survival (OS) is 13%. We analyzed high-dose chemotherapy (HDtx) versus conventional chemotherapy (CHtx) in patients with relapsed ES. PROCEDURE: Data from 239 patients with first relapse, registered during 2000-2011 in the ES relapse registry of the Cooperative Ewing Sarcoma Study Group (CESS) were analyzed. RESULTS: Of 239 patients, 200 received various non-HDtx second-line CHtx regimens. Seventy-three patients had additional HDtx followed by autologous stem cell rescue. The 2-year event-free survival (EFS) was 10% (SE = 0.02) in patients treated without HDtx and 45% (SE = 0.09) in patients treated with HDtx. In a second step, we focused on those patients who achieved complete remission (CR) or partial remission (PR) after four to six cycles of conventional second-line CHtx. Here, the 2-year EFS was 31% (SE = 0.08) without additional HDtx and 44% (SE = 0.09) with additional HDtx. In addition, multivariate regression analysis indicates absence of HDtx treatment, with a Hazard ratio (HR) of 2.90 (95% CI 1.41-6.0), and early relapse, with a HR of 4.76 (95% CI 2.31-9.78), as independent prognostic factors for EFS. CONCLUSION: Additional HDtx may contribute to further reduce the risk of further events in patients who respond to conventional second-line CHtx.
BACKGROUND: Prognosis of patients with relapsed Ewing sarcoma (ES) is poor. The 5-year overall survival (OS) is 13%. We analyzed high-dose chemotherapy (HDtx) versus conventional chemotherapy (CHtx) in patients with relapsed ES. PROCEDURE: Data from 239 patients with first relapse, registered during 2000-2011 in the ES relapse registry of the Cooperative Ewing Sarcoma Study Group (CESS) were analyzed. RESULTS: Of 239 patients, 200 received various non-HDtx second-line CHtx regimens. Seventy-three patients had additional HDtx followed by autologous stem cell rescue. The 2-year event-free survival (EFS) was 10% (SE = 0.02) in patients treated without HDtx and 45% (SE = 0.09) in patients treated with HDtx. In a second step, we focused on those patients who achieved complete remission (CR) or partial remission (PR) after four to six cycles of conventional second-line CHtx. Here, the 2-year EFS was 31% (SE = 0.08) without additional HDtx and 44% (SE = 0.09) with additional HDtx. In addition, multivariate regression analysis indicates absence of HDtx treatment, with a Hazard ratio (HR) of 2.90 (95% CI 1.41-6.0), and early relapse, with a HR of 4.76 (95% CI 2.31-9.78), as independent prognostic factors for EFS. CONCLUSION: Additional HDtx may contribute to further reduce the risk of further events in patients who respond to conventional second-line CHtx.
Authors: Maurizio Ghisoli; Minal Barve; Robert Mennel; Carl Lenarsky; Staci Horvath; Gladice Wallraven; Beena O Pappen; Sam Whiting; Donald Rao; Neil Senzer; John Nemunaitis Journal: Mol Ther Date: 2016-04-25 Impact factor: 11.454
Authors: Lianne M Haveman; Roelof van Ewijk; Elvira C van Dalen; Willemijn B Breunis; Leontien Cm Kremer; Henk van den Berg; Uta Dirksen; Johannes Hm Merks Journal: Cochrane Database Syst Rev Date: 2021-09-02
Authors: Jeremy Whelan; Marie-Cecile Le Deley; Uta Dirksen; Gwénaël Le Teuff; Bernadette Brennan; Nathalie Gaspar; Douglas S Hawkins; Susanne Amler; Sebastian Bauer; Stefan Bielack; Jean-Yves Blay; Stefan Burdach; Marie-Pierre Castex; Dagmar Dilloo; Angelika Eggert; Hans Gelderblom; Jean-Claude Gentet; Wolfgang Hartmann; Wolf-Achim Hassenpflug; Lars Hjorth; Marta Jimenez; Thomas Klingebiel; Udo Kontny; Jarmila Kruseova; Ruth Ladenstein; Valerie Laurence; Cyril Lervat; Perrine Marec-Berard; Sandrine Marreaud; Jean Michon; Bruce Morland; Michael Paulussen; Andreas Ranft; Peter Reichardt; Hendrik van den Berg; Keith Wheatley; Ian Judson; Ian Lewis; Alan Craft; Heribert Juergens; Odile Oberlin Journal: J Clin Oncol Date: 2018-09-06 Impact factor: 44.544
Authors: U Thiel; S J Schober; A Ranft; H Gassmann; S Jabar; K Gall; I von Lüttichau; A Wawer; E Koscielniak; M A Diaz; M Ussowicz; I Kazantsev; B Afanasyev; M Merker; T Klingebiel; A Prete; B Gruhn; P Bader; H Jürgens; U Dirksen; R Handgretinger; S Burdach; P Lang Journal: Bone Marrow Transplant Date: 2021-01-29 Impact factor: 5.483
Authors: Uta Dirksen; Bernadette Brennan; Marie-Cécile Le Deley; Nathalie Cozic; Henk van den Berg; Vivek Bhadri; Bénédicte Brichard; Line Claude; Alan Craft; Susanne Amler; Natalie Gaspar; Hans Gelderblom; Robert Goldsby; Richard Gorlick; Holcombe E Grier; Jean-Marc Guinbretiere; Peter Hauser; Lars Hjorth; Katherine Janeway; Heribert Juergens; Ian Judson; Mark Krailo; Jarmila Kruseova; Thomas Kuehne; Ruth Ladenstein; Cyril Lervat; Stephen L Lessnick; Ian Lewis; Claude Linassier; Perrine Marec-Berard; Neyssa Marina; Bruce Morland; Hélène Pacquement; Michael Paulussen; R Lor Randall; Andreas Ranft; Gwénaël Le Teuff; Keith Wheatley; Jeremy Whelan; Richard Womer; Odile Oberlin; Douglas S Hawkins Journal: J Clin Oncol Date: 2019-09-25 Impact factor: 50.717
Authors: Maurizio Ghisoli; Minal Barve; Reva Schneider; Robert Mennel; Carl Lenarsky; Gladice Wallraven; Beena O Pappen; John LaNoue; Padmasini Kumar; Derek Nemunaitis; Alyssa Roth; James Nemunaitis; Sam Whiting; Neil Senzer; Frederick A Fletcher; John Nemunaitis Journal: Mol Ther Date: 2015-03-19 Impact factor: 11.454